ALINT.PA stock surges 45% on high volume trading May 8

IntegraGen SA’s ALINT.PA stock delivered a powerful 45.06% surge on May 8, 2026, trading at €0.235 on EURONEXT with exceptional volume of 86,552 shares. This represents a €0.073 jump from the previous close of €0.162, marking one of the day’s most active movers in the biotechnology sector. The French genomics company, headquartered in Évry, provides human genome analysis services including DNA sequencing, transcriptomics, and NGS testing for cancer research. Today’s spike reflects strong intraday momentum as investors respond to elevated trading activity in this healthcare-focused equity.

ALINT.PA Stock Price Action and Volume Surge

ALINT.PA stock opened at €0.177 and climbed to a day high of €0.237, capturing significant intraday volatility. Trading volume reached 86,552 shares, substantially above the 13,375 average daily volume, indicating a 6x surge in market participation. The stock’s 45.06% gain positions it as a high-volume mover on EURONEXT today.

The price momentum reflects broader interest in IntegraGen SA’s genomic services platform. Year-to-date, ALINT.PA has gained 28.57%, though it remains down 71.96% over the past 12 months. The current price sits well below the €0.732 year high but above the €0.115 year low, showing recovery potential within its recent trading range.

IntegraGen SA Business Model and Market Position

IntegraGen SA operates as a specialized genomics service provider serving academic researchers and life sciences companies across Europe. The company offers MERCURY, an online interpretation tool for oncology pathologists, SIRIUS, a cloud-based sequencing analysis platform, and Galileo, an RNA-Seq exploration application. These proprietary tools differentiate IntegraGen in the competitive biotechnology landscape.

With 440 full-time employees and a market cap of €1.13 million, IntegraGen remains a micro-cap player. The company is a subsidiary of OncoDNA SA, providing strategic backing. Track ALINT.PA on Meyka for real-time updates on this genomics specialist’s trading activity and fundamental developments.

Technical Indicators and Market Sentiment

ALINT.PA’s technical setup shows mixed signals as of May 8. The RSI at 49.38 suggests neutral momentum, neither overbought nor oversold. The ADX at 26.23 indicates a strong trend forming, while the Stochastic %K at 33.33 points to potential upside room. The Money Flow Index at 64.32 signals strong buying pressure, supporting today’s volume surge.

Bollinger Bands position the stock near the middle band at €0.17, with upper resistance at €0.19 and lower support at €0.15. The Awesome Oscillator at -0.01 remains slightly negative, suggesting caution despite the day’s gains. These technical factors combined with elevated volume create a mixed but cautiously bullish environment for short-term traders.

Financial Metrics and Valuation Concerns

IntegraGen SA faces significant profitability challenges reflected in its financial metrics. The company reports a negative EPS of -€0.04 and a PE ratio of -4.28, indicating ongoing losses. The price-to-sales ratio of 0.225 appears attractive, but this masks deeper operational issues including negative operating cash flow and negative free cash flow.

Meyka AI rates ALINT.PA with a grade of B and a HOLD recommendation, with a rating score of 2 out of 5. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s ROE of 9.33% shows some shareholder value creation, though ROA of -0.95% reveals asset inefficiency. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

ALINT.PA stock’s 45% surge on May 8 reflects elevated trading activity rather than fundamental catalysts, as IntegraGen SA continues navigating profitability challenges. The 86,552 share volume demonstrates renewed investor interest in this genomics specialist, though the company’s negative earnings and cash flow warrant caution. While the technical setup shows strong momentum indicators like the MFI at 64.32, the underlying financial metrics remain concerning. Investors should monitor upcoming earnings announcements and cash position developments. The stock’s recovery from €0.115 year lows shows resilience, but sustainability depends on operational improvements and revenue growth…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.